Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
To determine the recommended phase 2 dose of chemotherapy in combination with Pembrolizumab in subjects with advanced lymphoma and determine the complete response rate.
Lymphoma|Hodgkin's Lymphoma|Non-hodgkin's Lymphoma
DRUG: Pembrolizumab|DRUG: Etoposide|DRUG: Ifosfamide|DRUG: Mesna|DRUG: Carboplatin|DRUG: Brentuximab vedotin|DRUG: Rituximab
Determine the recommended phase 2 dose (RP2D) of chemotherapy in combination with pembrolizumab (pembro) in subjects with advanced lymphoma and complete remission by Revised Response Criteria for Malignant Lymphoma., up to 12 weeks
Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03, up to 12 months|Response rate by immune-related response criteria (irRC), 12 weeks|Overall survival (OS) and progression-free survival (PFS), up to 12 months|Changes in number of copies of circulating tumor DNA in patients enrolled on this study, up to 12 months|Changes to pixel intensity identified on imaging that is done per routine practice, up to 12 weeks
To determine the recommended phase 2 dose of chemotherapy in combination with Pembrolizumab in subjects with advanced lymphoma and determine the complete response rate.